India has long been known as the “Pharmacy of the World,” a title earned through its immense contribution to global healthcare. The country produces nearly 20% of the generic medicines used worldwide, exports vaccines to more than 150 nations, and ranks among the largest pharmaceutical manufacturing centers on the planet. A crucial question deserves greater discussion: how many original pharmaceutical innovations has India introduced in recent years? Since 2021, the number stands at just eight.

These breakthroughs have come from a small group of domestic companies, including Zydus Lifesciences, Wockhardt, Orchid Pharma, Biocon, ImmunoACT, and ENTOD Pharmaceuticals. Their achievements span areas such as new drug molecules, biologics, cell-based therapies, immunotherapies, and advanced formulations, demonstrating that Indian researchers and companies are fully capable of producing world-class innovations.

Yet when compared with global innovation leaders, the gap becomes apparent. Over the same period, the United States generated roughly 500 significant pharmaceutical innovations, including around 160 new chemical entities (NCEs). China recorded nearly 150 innovations, with close to 95 homegrown NCEs. India, despite its scientific expertise and strong manufacturing foundation, remains far behind.

The issue is not a lack of talent or scientific capability. Instead, the challenge lies within the broader innovation ecosystem. Creating a new medicine requires years of research, extensive clinical testing, regulatory approvals, and substantial financial investment, often with no certainty of success. One policy issue that receives limited attention in India is clinical data exclusivity. In leading pharmaceutical markets such as the United States, European Union, and China, innovators receive a period during which competitors cannot rely on the original developer’s clinical trial data to secure regulatory approval for similar products. This protection differs from patents and recognizes the enormous time and resources invested in generating clinical evidence, often consuming a significant portion of a product’s patent life.

India currently lacks a comparable system for most locally developed pharmaceutical innovations. Supporters of data exclusivity argue that a well-balanced framework would not significantly affect long-term medicine affordability or access. Competition would still enter the market after a defined period, as it does elsewhere. However, such protection could encourage greater investment in drug discovery, address unmet medical needs, close therapeutic gaps, improve patient outcomes, and strengthen India’s position in high-value pharmaceutical innovation.

It is therefore unsurprising that many Indian companies actively engaged in research and development support the introduction of such measures. Their argument is simple: without meaningful incentives and protection, innovation will remain rare rather than becoming a widespread industry objective.

India has already proven its strength in reverse engineering and generic drug manufacturing, a success that helped establish its global pharmaceutical reputation. The next phase of growth should focus on innovation-driven development—discovering new molecules, advancing biologics and cutting-edge therapies, and creating medicines that originate in Indian laboratories before reaching patients around the world. The country’s ambition should extend beyond being a manufacturing powerhouse. India now has the opportunity to become a global center for pharmaceutical invention, recognized not only for producing medicines but also for creating them.